Zaoke He

Results To identify the metabolic genes critical for tumor hypoxic adaptation, we systematically compared the metabolic enzyme networks between hypoxic and non-hypoxic samples. The cancer genome atlas (TCGA) sample-specific genome-scale metabolic models (GEMs) were retrieved from Francesco Gatto et al. work,17 which contains 4,849 TCGA tumor samples, and then converted GEMs to metabolic enzyme networks.

Abstract Receptor-interacting protein kinase 2 (RIPK2) has emerged as a promising drug target in various cancers, including prostate cancer (PC). However, the absence of reliable biomarkers to assess RIPK2 activity limits both patient selection for anti-RIPK2 therapies and treatment monitoring.

Immunotherapy has revolutionized the treatment of cancer, and this success is represented by immune checkpoint inhibitors (ICI) (including anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies and their combinations), which show higher efficacy than standard therapies in several cancers, including lung cancer. However, the majority of patients do not respond to immunotherapy, and biomarkers for predicting immunotherapy clinical response are urgently needed.